http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2679228-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfd4c6559bd98afae743866baff20261 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc5d0d0af41aff597af9da0f3c5c16b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-20 |
| filingDate | 2007-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7886e70c37c8c352328c52097f9211a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7536a42c781c3708362331225ec38f6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8641d1e0c060a230c55acf0ffa3d7ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6993e624db114e9e85e12fc554da4d8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b04f99a3b9cb3f2b2da4341d632faade |
| publicationDate | 2014-01-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2679228-A1 |
| titleOfInvention | Therapy using vitamin D repletion agent and vitamin D hormone replacement agent |
| abstract | A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance. |
| priorityDate | 2006-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 300 of 300.